T3 Companies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-15,000
Closed -$150K – 207
2026
Q2
$150K Buy
+15,000
New +$136K 0.16% 102

Other funds holding BCRX

T3 Companies's BCRX Position: Q3 2026 in Review

T3 Companies sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2026, closing a stake of 15,000 shares — an estimated $150K sold.

T3 Companies first reported a position in BCRX in Q2 2026 and held it in 1 quarter. The position peaked at $150K in Q2 2026. 334 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • T3 Companies reported no remaining BioCryst Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • T3 Companies sold 15,000 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $150K.
  • T3 Companies first reported a position in BioCryst Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • T3 Companies's BioCryst Pharmaceuticals position peaked at $150K in Q2 2026.
  • 334 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on T3 Companies's 13F filing for Q3 2026, filed 22 Oct 2026.